PPIA and prostate carcinoma: To date, multiple studies have highlighted the association of CypA over-expression and tumourigenesis in humans, including haematopoietic [26], lung [30], endometrial [31] and prostate cancer [32], and CypA has been proposed as a therapeutic target [24,25].